追溯码助力严查“回流药”—— 让药品来源可查去向可追

Core Viewpoint - The National Healthcare Security Administration (NHSA) is conducting a nationwide special rectification of medical insurance fund management, focusing on issues related to "abnormal drug traceability codes" and illegal resale of "returned drugs" [1][2]. Group 1: Regulatory Actions - The NHSA, in collaboration with various government departments, has initiated a three-phase comprehensive investigation into designated medical institutions suspected of selling "returned drugs" [1]. - The first phase of the investigation has been completed, with the second phase scheduled for deployment in August 2025, and a concentrated action planned from October to December [1]. - The NHSA has collected a total of 39.885 billion drug traceability codes since the nationwide implementation of drug traceability code collection began in 2024 [1]. Group 2: Drug Traceability System - The drug traceability code serves as a unique "electronic ID" for each box of medication, ensuring that each drug can only be sold once; repeated scans may indicate counterfeit or "returned drugs" [2]. - The NHSA has implemented a policy where medical insurance funds will refuse payment for drugs that are not scanned or show repeated scans, thereby enhancing drug regulation efficiency [2]. - As of July 1, 2025, designated medical institutions are required to scan drugs during the sales process to facilitate medical insurance fund settlement [2]. Group 3: Public Engagement and Compliance - A societal consensus has emerged around the principle of "verify the code before buying, scan the code before selling," with approximately 5 million consumers checking drug authenticity daily [3]. - The NHSA aims to strengthen the use of drug traceability codes for regulatory purposes and will collaborate with relevant departments to combat the resale of "returned drugs" comprehensively [3]. - The NHSA has advised that any anomalies in scanning should lead to the rejection of goods, and evidence should be collected for reporting to authorities, with penalties for those involved in the sale of "returned drugs" [2].